Johnson & Johnson (JNJ) 99.90 $JNJ
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - 21 mins ago
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.35 (unch), KNMD: (), VTAE: 9.84 (-0.06), LLY: 84.98 (-0.70), OMER: 16.15 (-0.21), JNJ: 99.90 (+0.88), ISIS: 52.73 (-1.67), OPK: 16.67 (-0.17), GILD: 116.71 (+3.64), AZN: 32.84 (+0.03), MRK: 58.72 (+1.20), CCXI: 8.52 (-0.10), VBLT: 6.13 (-0.02), NVS: 103.77 (+0.98)
Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer
PR Newswire - 23 mins ago
Turing Pharmaceuticals AG announced today that Craig A. Rothenberg has joined the company as its first Chief Communication Officer.
JNJ: 99.90 (+0.88)
NuVasive Hits 7-Year High After Q2 Earnings Beat
at Investor's Business Daily - 1 hr 47 mins ago
Spinal-product specialist NuVasive (NUVA) got an upgrade and two price-target increases Wednesday after its Q2 earnings beat estimates late Tuesday. The stock hit a seven-year high in early trading. NuVasive's profit rose 11% over the year-earlier...
JNJ: 99.90 (+0.88), NUVA: 54.56 (+4.09)
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $99.70
Comtex SmarTrend(R) - 2 hrs 42 mins ago
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $98.89 today and have reached the first resistance level of $99.36. Should the shares continue to rise, the resistance pivots of $99.70 and $100.51 will be of interest.
JNJ: 99.90 (+0.88)
Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up
at Investor's Business Daily - Tue Jul 28, 3:03PM CDT
Cataplexy -- sudden temporary muscle weakness -- is one of the most devastating symptoms of narcolepsy, a neurological disorder that disrupts sleep and wake cycles. Victims are prone to fall asleep suddenly in the middle of the day -- while driving,...
JNJ: 99.90 (+0.88), JAZZ: 189.05 (-3.97), TEVA: 71.03 (-0.38), CNCE: 16.57 (-0.48)
Canada Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
M2 - Tue Jul 28, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wll8sz/canada_home) has announced the addition of the "Canada Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The Canada home healthcare market is estimated to be USD 10,449.1 million in 2013 and is expected to reach USD 18,939.9 million by 2020, growing at a CAGR of 8.9% from 2014 to 2020. The Canada home healthcare market has been studied from three perspectives: by device types, by services and by provinces. Based on device types, the market has been segmented into four categories: diagnostic and monitoring devices, therapeutic home healthcare devices, home mobility assist devices and medical supplies. Among these, diagnostics and monitoring devices are accounted for the largest market, capturing over 30% of the total Canada home medical devices market in 2013. Efforts of the Canadian government to increase awareness about hypertension, diabetes and sleep apnea management through home monitoring drives the growth of diagnostics and monitoring devices segment. Moreover, home mobility assist devices market segment recorded the lowest revenue in 2013 owing to the low cost of market constituents such as cranes and crutches, walkers and rollators and others. Based on services, the Canada home healthcare market is categorized into rehabilitation, telehealth and telemedicine, respiratory therapy, infusion therapy and unskilled home healthcare services. In 2013, unskilled home healthcare services market accounted for the largest market and is expected to dominate the market in future. Growing geriatric population coupled with increasing uptake of nonprofessional home care services in Canada helps this segment to grow consistently during the forecast period. Moreover, telehealth and telemedicine services only accounted for 2% revenue of the total home healthcare services market in 2013 but is expected to grow with the highest CAGR of around 11% during the forecast period from 2014 to 2020. Fundamental benefits availed from these services such as high cost-effectiveness, quality health care and access to health care services throughout rural and urban areas supports the growth of the market in Canada. In terms of geographic distribution, the Canada home healthcare market has been segmented into four provinces i.e. Ontario, Quebec, Alberta and Rest of Canada. The Ontario home healthcare market in 2013 accounted for the largest market share due to high demand for home healthcare devices and services. Moreover, consistent rise in geriatric population and favorable government policies propels the growth of home healthcare market in Ontario. Followed by Ontario, Rest of Canada turned out to be the second largest market due to increasing number of obese population over the last few years. The Canada home healthcare market in Quebec is expected to grow at the highest CAGR of 9.2% from 2014 to 2020. The growth of this province is mainly attributed to the large population base and increasing incidence rate of chronic diseases. Companies Mentioned - 3M - Abbott Laboratories - Cardinal Health - General Electric Company - Invacare Corporation - Johnson & Johnson - Medtronic plc For more information visit http://www.researchandmarkets.com/research/wl...anada_home
JNJ: 99.90 (+0.88), ABT: 50.94 (unch), GE: 26.16 (+0.06), MDT: 77.09 (-0.38), IVC: 17.02 (-0.37)
Medical Devices Market in Japan 2015-2019 - What are the market opportunities and threats faced by the key vendors?
M2 - Tue Jul 28, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lk6wws/medical_devices) has announced the addition of the "Medical Devices Market in Japan 2015-2019" report to their offering. The medical devices market in Japan to grow at a CAGR of 2.49% over the period 2014-2019. This report covers the present scenario and the growth prospects of the medical devices market in Japan for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of medical devices for various applications. Based on devices, the market can be segmented into 10: cardiovascular devices, diagnostic imaging systems, orthopedic implants, patient monitoring devices, respiratory devices, home care products, dental materials and equipment, wound care products, ophthalmic equipment and supplies, and others (therapeutic and surgical equipment, and operating equipment and supplies). The Japanese healthcare system is centered on improving the quality of treatment for customers with more emphasis on the elderly. Equipment that assists biofunctions such as cardiac valve prosthetics, orthopedic implants, and pacemakers obtain instant regulatory clearance. Thus, vendors developing devices for age-related disorders have immense opportunities to launch innovative products in Japan. This could also propel imports from countries such as the US and China into Japan. According to the report, Japan has seen tremendous improvements in the healthcare infrastructure and is engaged in continuous R&D. People in Japan favor the use of medical technology such as CT and MRI for diagnosis and treatment. Most surgeries in the country employ accurate, precise, and reliable robotic surgical devices. Developments such as hypodermic needles with serrated edges (to reduce pain) and self-propelled capsule endoscopes are other major developments in the market. All these factors favor the growth of the market in this country. Further, the report states that the option of choosing a healthcare provider of the patient's choice adds to the burden of healthcare providers. The report, Medical Devices Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top 10 vendors in the market. Key Vendors International Vendors - Baxter International - GE Healthcare - Johnson & Johnson - Medtronic - Siemens Healthcare Domestic Vendors - Hitachi Medico - Nipro - Olympus Medical Systems - Terumo - Toshiba Medical Systems Other Prominent Vendors - Alfresa Holdings - Aloka - Canon Medical Systems - Fukuda Denshi - Hogy Medical - Hoya - Ikaria - Konica Minolta - Mevion Medical Systems - Nidek - Nihon Kohden - Omron - Shimadzu - TeraRecon - Toray Medical - Toxikon For more information visit http://www.researchandmarkets.com/research/lk...al_devices
JNJ: 99.90 (+0.88), MDT: 77.09 (-0.38), BAX: 38.51 (+0.42)
Epoetin Alfa Dominates the Global Erythropoietin Market
M2 - Tue Jul 28, 3:01AM CDT
According to a new research report by RNCOS entitled, "Global Erythropoietin Market Outlook 2020", the US dominates the erythropoietin market in the world whereas the emerging countries of Asia Pacific region are moving towards manufacturing of EPO biosimilars hindering the global erythropoietin market.
JNJ: 99.90 (+0.88)
J&J Snack Foods posts 3Q profit
Automated Insights - Mon Jul 27, 3:07PM CDT
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Monday reported fiscal third-quarter net income of $24.5 million.
JNJ: 99.90 (+0.88), JJSF: 116.17 (+0.27)
Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 10:20AM CDT
We expect PerkinElmer Inc. (VAR) to beat the Zacks Consensus Estimate when it reports second-quarter 2015 results on Jul 29.
JNJ: 99.90 (+0.88), LDRH: 44.64 (-0.69), AMAG: 64.37 (-1.86), PKI: 50.68 (-0.02)
Acidity Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zs3x7/acidity_global) has announced the addition of the "Acidity Global Clinical Trials Review, H1, 2015" report to their offering. "Acidity Global Clinical Trials Review, H1, 2015" provides data on the Acidity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acidity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acidity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Acidity Therapeutics Clinical Trials - Dr. Reddy's Laboratories Limited - Merck & Co., Inc. - Johnson & Johnson - Pozen, Inc. - Emcure Pharmaceuticals Ltd. - Eisai Co., Ltd. - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - AstraZeneca PLC - Abbott Laboratories - Academic Medical Center - Central Council for Research in Unani Medicine - Changhai Hospital - Gujarat Ayurved University - Tehran University of Medical Sciences - University Hospital Koge For more information visit http://www.researchandmarkets.com/research/3z...ity_global
JNJ: 99.90 (+0.88), ABT: 50.94 (unch), MRK: 58.72 (+1.20), AZN: 32.84 (+0.03), POZN: 11.75 (-0.42)
Appendicitis Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzv2k/appendicitis) has announced the addition of the "Appendicitis Global Clinical Trials Review, H1, 2015" report to their offering. "Appendicitis Global Clinical Trials Review, H1, 2015" provides data on the Appendicitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Appendicitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Appendicitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Appendicitis Therapeutics Clinical Trials - Johnson & Johnson - Pfizer Inc. - The Children's Mercy Hospital - University of California, San Diego - Academic Medical Center - HaEmek Medical Center - Karolinska University Hospital - Kashan University of Medical Sciences and Health Services - Nationwide Children's Hospital - Assistance Publique - Hopitaux de Paris - Centre Hospitalier Universitaire de Nantes - Centre Hospitalier Universitaire, Amiens For more information visit http://www.researchandmarkets.com/research/lt...pendicitis
JNJ: 99.90 (+0.88), PFE: 35.68 (+0.33)
Complex Regional Pain Syndrome - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwct8h/complex_regional) has announced the addition of the "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Complex Regional Pain Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Complex Regional Pain Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Complex Regional Pain Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Complex Regional Pain Syndrome Therapeutics Clinical Trials - Johnson & Johnson - Celgene Corporation - Endo International plc - Leiden University Medical Center - Academic Hospital Maastricht - Massachusetts General Hospital - Mayo Clinic - Medical University of Vienna - Aalto University School of Science and Technology - Centre Hospitalier Universitaire, Amiens - Charite - Universitatsmedizin Berlin - Danish Pain Research Center - Drexel University College of Medicine For more information visit http://www.researchandmarkets.com/research/vw...x_regional
JNJ: 99.90 (+0.88), CELGZ: 2.06 (+0.02)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 7.00 (unch), SNN: 35.35 (+0.17), JNJ: 99.90 (+0.88), MMM: 151.33 (+0.22), OSIR: 21.21 (-0.29), MDXG: 12.25 (-0.55), NVDQ: 12.50 (+0.57)
Global Cosmetics Market 2015-2020: Market was $460 Billion in 2014 and is Estimated to Reach $675 Billion by 2020
M2 - Mon Jul 27, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgszcl/global_cosmetics) has announced the addition of the "Global Cosmetics Market - By Product type, Ingredient, Geography, And Vendors - Market Size, Demand Forecasts, Industry Trends and Updates, Supplier Market Shares 2014- 2020" report to their offering. The global Cosmetic market was 460 billion USD in 2014 and is estimated to reach 675 billion USD by 2020 growing at a rate of 6.4%. Of the cosmetic products, Skin care has the highest market share while Oral Cosmetics would be the fasted growing market during the forecasted period. Growth by Region: APAC leads the cosmetic industry with a market share of 35% in 2014, followed by Western Europe and North America. The high market share of Asia Pacific region is attributed to the fact that customers are relatively beauty conscious. Moreover, with the expected growth rate being highest among all regions, APAC is the region of focus for the cosmetics providers. Drivers vs. Constraints: - E-Retail / Online Shopping - Rise in disposable income - Travel Retail - Product Innovation - Consumer perception of the products causing side effects - Unregulated market The sale of cosmetics is seeing a shift from being traditionally purchased to buying online. Moreover, increase in spending income, especially in the developing countries is driving the market. In addition to the above factors, other factors acting as drivers/constraints to the industry are available in the report along with a detailed description of their impact on the market. Industry Trends and Updates: - Product Innovations Companies are focusing on bringing in products specific to the consumer requirement. Gender specific products are also increasing at a rapid pace. - Organic products Growing concerns on the long term effects due to usage of cosmetics is forcing the companies to bring in organic products as well. This market is expected to increase during the forecasted period - Focus on Packaging Cosmetics Manufacturers profiling: The report also provides supplier intelligence which includes information such as top players in the industry (Procter and Gamble, Johnson and Johnson, L'Oreal, Avon, Henkel, Estee Lauder, etc among others). This also gives information on the supplier's market share, competitive landscape as well. Key Topics Covered: 1. Introduction - Research Methodology 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Cosmetics Market Segmentation, Forecasts and Trends - by Volume, by Revenue 6. Global Vendor Market Share Analysis 7. Competitive Intelligence - Company Profiles 8. Investment Analysis 9. Future of Cosmetics Market Companies Mentioned - Avon - Bayer - Clarins - Estee Lauder - Henkel - Hindistan Unilever - Johnson and Johnson - L'Oreal - Procter and Gamble For more information visit http://www.researchandmarkets.com/research/jg..._cosmetics
JNJ: 99.90 (+0.88), EL: 89.35 (+1.33)
4 Great Stocks For Beginners
Matthew Frankel, The Motley Fool - Motley Fool - Sun Jul 26, 7:09AM CDT
If you're new to the stock market, it may be tempting to pour your money into "it" stocks like Netflix , Tesla , and Amazon.com . However, that's the exact opposite of what you should be doing. Instead, the primary objective of a new investor...
JNJ: 99.90 (+0.88), XOM: 82.54 (+0.06), CL: 68.97 (+0.58)
Is Bristol-Myers Squibb Outpacing Johnson & Johnson?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 25, 9:03AM CDT
Source: Flickr user Paul A race for dominance in the anticoagulant market is heating up between Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) with the winner standing to reap billions of dollars in additional revenue...
JNJ: 99.90 (+0.88), BMY: 64.48 (-0.18)
A look at the largest companies in the S&P 500
By The Associated Press - AP - Fri Jul 24, 6:08PM CDT
Amazon surpassed the world's largest retailer, Wal-Mart Stores Inc., in market value Friday, on the back of a strong earnings report. Amazon shares closed up nearly 10 percent, giving the Seattle company a market value of $247.77 billion, versus $230.53 billion for Wal-Mart.
AMZN: 527.40 (+1.37), GE: 26.16 (+0.06), FB: 95.91 (+0.62), PFE: 35.68 (+0.33), DIS: 119.29 (+0.83), WMT: 72.38 (+0.28), XOM: 82.54 (+0.06), BAC: 18.10 (+0.22), WFC: 57.99 (+0.59), GOOG: 624.31 (-3.69), JNJ: 99.90 (+0.88), GOOGL: 654.81 (-4.85), PG: 80.85 (+0.62), MSFT: 46.50 (+1.16), AAPL: 122.51 (-0.87)
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
By LINDA A. JOHNSON - AP - Fri Jul 24, 4:57PM CDT
TRENTON, N.J. (AP) — An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely costly — for patients with the liver-destroying virus.
JNJ: 99.90 (+0.88), GILD: 116.71 (+3.64), MRK: 58.72 (+1.20), BMY: 64.48 (-0.18)
After Yesterday's Decline of 1.04%, Johnson & Johnson Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jul 24, 4:56PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.05 to a high of $99.95. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $99.73 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 99.90 (+0.88)
Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com
PRWeb - 21 mins ago
The report "Atherosclerosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start in childhood. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread across 276 pages is available at http://www.rnrmarketresearch.com/atherosclero...eport.html .
VCEL: 3.35 (unch), KNMD: (), VTAE: 9.84 (-0.06), LLY: 84.98 (-0.70), OMER: 16.15 (-0.21), JNJ: 99.90 (+0.88), ISIS: 52.73 (-1.67), OPK: 16.67 (-0.17), GILD: 116.71 (+3.64), AZN: 32.84 (+0.03), MRK: 58.72 (+1.20), CCXI: 8.52 (-0.10), VBLT: 6.13 (-0.02), NVS: 103.77 (+0.98)
Turing Pharmaceuticals Names Craig Rothenberg Chief Communication Officer
PR Newswire - 23 mins ago
Turing Pharmaceuticals AG announced today that Craig A. Rothenberg has joined the company as its first Chief Communication Officer.
JNJ: 99.90 (+0.88)
NuVasive Hits 7-Year High After Q2 Earnings Beat
at Investor's Business Daily - 1 hr 47 mins ago
Spinal-product specialist NuVasive (NUVA) got an upgrade and two price-target increases Wednesday after its Q2 earnings beat estimates late Tuesday. The stock hit a seven-year high in early trading. NuVasive's profit rose 11% over the year-earlier...
JNJ: 99.90 (+0.88), NUVA: 54.56 (+4.09)
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $99.70
Comtex SmarTrend(R) - 2 hrs 42 mins ago
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $98.89 today and have reached the first resistance level of $99.36. Should the shares continue to rise, the resistance pivots of $99.70 and $100.51 will be of interest.
JNJ: 99.90 (+0.88)
Wakefulness Drug Xyrem Keeps Jazz Pharmaceuticals Up
at Investor's Business Daily - Tue Jul 28, 3:03PM CDT
Cataplexy -- sudden temporary muscle weakness -- is one of the most devastating symptoms of narcolepsy, a neurological disorder that disrupts sleep and wake cycles. Victims are prone to fall asleep suddenly in the middle of the day -- while driving,...
JNJ: 99.90 (+0.88), JAZZ: 189.05 (-3.97), TEVA: 71.03 (-0.38), CNCE: 16.57 (-0.48)
Canada Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020
M2 - Tue Jul 28, 5:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wll8sz/canada_home) has announced the addition of the "Canada Home Healthcare Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The Canada home healthcare market is estimated to be USD 10,449.1 million in 2013 and is expected to reach USD 18,939.9 million by 2020, growing at a CAGR of 8.9% from 2014 to 2020. The Canada home healthcare market has been studied from three perspectives: by device types, by services and by provinces. Based on device types, the market has been segmented into four categories: diagnostic and monitoring devices, therapeutic home healthcare devices, home mobility assist devices and medical supplies. Among these, diagnostics and monitoring devices are accounted for the largest market, capturing over 30% of the total Canada home medical devices market in 2013. Efforts of the Canadian government to increase awareness about hypertension, diabetes and sleep apnea management through home monitoring drives the growth of diagnostics and monitoring devices segment. Moreover, home mobility assist devices market segment recorded the lowest revenue in 2013 owing to the low cost of market constituents such as cranes and crutches, walkers and rollators and others. Based on services, the Canada home healthcare market is categorized into rehabilitation, telehealth and telemedicine, respiratory therapy, infusion therapy and unskilled home healthcare services. In 2013, unskilled home healthcare services market accounted for the largest market and is expected to dominate the market in future. Growing geriatric population coupled with increasing uptake of nonprofessional home care services in Canada helps this segment to grow consistently during the forecast period. Moreover, telehealth and telemedicine services only accounted for 2% revenue of the total home healthcare services market in 2013 but is expected to grow with the highest CAGR of around 11% during the forecast period from 2014 to 2020. Fundamental benefits availed from these services such as high cost-effectiveness, quality health care and access to health care services throughout rural and urban areas supports the growth of the market in Canada. In terms of geographic distribution, the Canada home healthcare market has been segmented into four provinces i.e. Ontario, Quebec, Alberta and Rest of Canada. The Ontario home healthcare market in 2013 accounted for the largest market share due to high demand for home healthcare devices and services. Moreover, consistent rise in geriatric population and favorable government policies propels the growth of home healthcare market in Ontario. Followed by Ontario, Rest of Canada turned out to be the second largest market due to increasing number of obese population over the last few years. The Canada home healthcare market in Quebec is expected to grow at the highest CAGR of 9.2% from 2014 to 2020. The growth of this province is mainly attributed to the large population base and increasing incidence rate of chronic diseases. Companies Mentioned - 3M - Abbott Laboratories - Cardinal Health - General Electric Company - Invacare Corporation - Johnson & Johnson - Medtronic plc For more information visit http://www.researchandmarkets.com/research/wl...anada_home
JNJ: 99.90 (+0.88), ABT: 50.94 (unch), GE: 26.16 (+0.06), MDT: 77.09 (-0.38), IVC: 17.02 (-0.37)
Medical Devices Market in Japan 2015-2019 - What are the market opportunities and threats faced by the key vendors?
M2 - Tue Jul 28, 3:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lk6wws/medical_devices) has announced the addition of the "Medical Devices Market in Japan 2015-2019" report to their offering. The medical devices market in Japan to grow at a CAGR of 2.49% over the period 2014-2019. This report covers the present scenario and the growth prospects of the medical devices market in Japan for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of medical devices for various applications. Based on devices, the market can be segmented into 10: cardiovascular devices, diagnostic imaging systems, orthopedic implants, patient monitoring devices, respiratory devices, home care products, dental materials and equipment, wound care products, ophthalmic equipment and supplies, and others (therapeutic and surgical equipment, and operating equipment and supplies). The Japanese healthcare system is centered on improving the quality of treatment for customers with more emphasis on the elderly. Equipment that assists biofunctions such as cardiac valve prosthetics, orthopedic implants, and pacemakers obtain instant regulatory clearance. Thus, vendors developing devices for age-related disorders have immense opportunities to launch innovative products in Japan. This could also propel imports from countries such as the US and China into Japan. According to the report, Japan has seen tremendous improvements in the healthcare infrastructure and is engaged in continuous R&D. People in Japan favor the use of medical technology such as CT and MRI for diagnosis and treatment. Most surgeries in the country employ accurate, precise, and reliable robotic surgical devices. Developments such as hypodermic needles with serrated edges (to reduce pain) and self-propelled capsule endoscopes are other major developments in the market. All these factors favor the growth of the market in this country. Further, the report states that the option of choosing a healthcare provider of the patient's choice adds to the burden of healthcare providers. The report, Medical Devices Market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report presents the vendor landscape and a corresponding detailed analysis of the top 10 vendors in the market. Key Vendors International Vendors - Baxter International - GE Healthcare - Johnson & Johnson - Medtronic - Siemens Healthcare Domestic Vendors - Hitachi Medico - Nipro - Olympus Medical Systems - Terumo - Toshiba Medical Systems Other Prominent Vendors - Alfresa Holdings - Aloka - Canon Medical Systems - Fukuda Denshi - Hogy Medical - Hoya - Ikaria - Konica Minolta - Mevion Medical Systems - Nidek - Nihon Kohden - Omron - Shimadzu - TeraRecon - Toray Medical - Toxikon For more information visit http://www.researchandmarkets.com/research/lk...al_devices
JNJ: 99.90 (+0.88), MDT: 77.09 (-0.38), BAX: 38.51 (+0.42)
Epoetin Alfa Dominates the Global Erythropoietin Market
M2 - Tue Jul 28, 3:01AM CDT
According to a new research report by RNCOS entitled, "Global Erythropoietin Market Outlook 2020", the US dominates the erythropoietin market in the world whereas the emerging countries of Asia Pacific region are moving towards manufacturing of EPO biosimilars hindering the global erythropoietin market.
JNJ: 99.90 (+0.88)
J&J Snack Foods posts 3Q profit
Automated Insights - Mon Jul 27, 3:07PM CDT
PENNSAUKEN, N.J. (AP) _ J&J Snack Foods Corp. (JJSF) on Monday reported fiscal third-quarter net income of $24.5 million.
JNJ: 99.90 (+0.88), JJSF: 116.17 (+0.27)
Is PerkinElmer (PKI) Poised to Beat Q2 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 27, 10:20AM CDT
We expect PerkinElmer Inc. (VAR) to beat the Zacks Consensus Estimate when it reports second-quarter 2015 results on Jul 29.
JNJ: 99.90 (+0.88), LDRH: 44.64 (-0.69), AMAG: 64.37 (-1.86), PKI: 50.68 (-0.02)
Acidity Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3zs3x7/acidity_global) has announced the addition of the "Acidity Global Clinical Trials Review, H1, 2015" report to their offering. "Acidity Global Clinical Trials Review, H1, 2015" provides data on the Acidity clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acidity. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acidity. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Acidity Therapeutics Clinical Trials - Dr. Reddy's Laboratories Limited - Merck & Co., Inc. - Johnson & Johnson - Pozen, Inc. - Emcure Pharmaceuticals Ltd. - Eisai Co., Ltd. - C. H. Boehringer Sohn AG & Co. KG - Bayer AG - AstraZeneca PLC - Abbott Laboratories - Academic Medical Center - Central Council for Research in Unani Medicine - Changhai Hospital - Gujarat Ayurved University - Tehran University of Medical Sciences - University Hospital Koge For more information visit http://www.researchandmarkets.com/research/3z...ity_global
JNJ: 99.90 (+0.88), ABT: 50.94 (unch), MRK: 58.72 (+1.20), AZN: 32.84 (+0.03), POZN: 11.75 (-0.42)
Appendicitis Clinical Trials - Global Review, H1, 2015
M2 - Mon Jul 27, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzv2k/appendicitis) has announced the addition of the "Appendicitis Global Clinical Trials Review, H1, 2015" report to their offering. "Appendicitis Global Clinical Trials Review, H1, 2015" provides data on the Appendicitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Appendicitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Appendicitis. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Appendicitis Therapeutics Clinical Trials - Johnson & Johnson - Pfizer Inc. - The Children's Mercy Hospital - University of California, San Diego - Academic Medical Center - HaEmek Medical Center - Karolinska University Hospital - Kashan University of Medical Sciences and Health Services - Nationwide Children's Hospital - Assistance Publique - Hopitaux de Paris - Centre Hospitalier Universitaire de Nantes - Centre Hospitalier Universitaire, Amiens For more information visit http://www.researchandmarkets.com/research/lt...pendicitis
JNJ: 99.90 (+0.88), PFE: 35.68 (+0.33)
Complex Regional Pain Syndrome - Global Clinical Trials Review, H1, 2015
M2 - Mon Jul 27, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vwct8h/complex_regional) has announced the addition of the "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" report to their offering. "Complex Regional Pain Syndrome Global Clinical Trials Review, H1, 2015" provides data on the Complex Regional Pain Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Complex Regional Pain Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Complex Regional Pain Syndrome. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Complex Regional Pain Syndrome Therapeutics Clinical Trials - Johnson & Johnson - Celgene Corporation - Endo International plc - Leiden University Medical Center - Academic Hospital Maastricht - Massachusetts General Hospital - Mayo Clinic - Medical University of Vienna - Aalto University School of Science and Technology - Centre Hospitalier Universitaire, Amiens - Charite - Universitatsmedizin Berlin - Danish Pain Research Center - Drexel University College of Medicine For more information visit http://www.researchandmarkets.com/research/vw...x_regional
JNJ: 99.90 (+0.88), CELGZ: 2.06 (+0.02)
Wound Care - Traditonal, Advanced And Regenerative: Global Markets, Competitors And Opportunities: 2015-2020
M2 - Mon Jul 27, 5:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/v6v8fh/wound_care) has announced the addition of the "Wound Care -Traditonal, Advanced And Regenerative-Global Markets, Competitors And Opportunities: 2015-2020 Analysis And Forecasts" report to their offering. Comprehensive information and evaluation of the global Wound Care products market, with detailed analysis of manufacturers, segmentation, product offerings, competitive shares, financial performance, technology developments and market drivers. Additionally, 20 key Wound Care product suppliers are fully analyzed and profiled. A must-read compendium of information and analysis that will provide executives with a significant knowledge of global market, product, technology and financial developments in this industry. Hard factual information in 202 pages, illustrated with 53 tables and 42 charts and figures. The only published report of its kind, with in-depth detail not found elsewhere in similar studies. Products Covered: - Bandages, Tapes, Gauze - Alginate Dressings - Foam Dressings - Antimicrobial Dressings - Hydrogels - Hydrocolloids - Bioengineered Skin - Skin Substitutes - Biologic Substances - Pulsed Radio Frequency Energy - Pulsed Electrmagnetic Fields - Wound Closure - Wound Management - Pressure Relief - Sutures, Staples, Adhesives, - Collagen Sealants Companies Mentioned - 3M Company - Advanced Medical Solutions Group plc - Alliqua BioMedical, Inc. - Avita Medical Ltd. - Centaur Guernsey L.P. Inc. - Coloplast A/S - Covidien plc - CytoTools AG - Cytomedix, Inc. - Derma Sciences, Inc. - Essex Bio-Technology Ltd. - Japan Tissue Engineering Co., Ltd. - Johnson & Johnson - Macrocure Ltd - MiMedx Group, Inc. - Novadaq Technologies Inc. - Osiris Therapeutics, Inc. - SANUWAVE Health, Inc. - Smith & Nephew Plc - Tissue Regenix Group plc For more information visit http://www.researchandmarkets.com/research/v6v8fh/wound_care
DSCI: 7.00 (unch), SNN: 35.35 (+0.17), JNJ: 99.90 (+0.88), MMM: 151.33 (+0.22), OSIR: 21.21 (-0.29), MDXG: 12.25 (-0.55), NVDQ: 12.50 (+0.57)
Global Cosmetics Market 2015-2020: Market was $460 Billion in 2014 and is Estimated to Reach $675 Billion by 2020
M2 - Mon Jul 27, 4:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jgszcl/global_cosmetics) has announced the addition of the "Global Cosmetics Market - By Product type, Ingredient, Geography, And Vendors - Market Size, Demand Forecasts, Industry Trends and Updates, Supplier Market Shares 2014- 2020" report to their offering. The global Cosmetic market was 460 billion USD in 2014 and is estimated to reach 675 billion USD by 2020 growing at a rate of 6.4%. Of the cosmetic products, Skin care has the highest market share while Oral Cosmetics would be the fasted growing market during the forecasted period. Growth by Region: APAC leads the cosmetic industry with a market share of 35% in 2014, followed by Western Europe and North America. The high market share of Asia Pacific region is attributed to the fact that customers are relatively beauty conscious. Moreover, with the expected growth rate being highest among all regions, APAC is the region of focus for the cosmetics providers. Drivers vs. Constraints: - E-Retail / Online Shopping - Rise in disposable income - Travel Retail - Product Innovation - Consumer perception of the products causing side effects - Unregulated market The sale of cosmetics is seeing a shift from being traditionally purchased to buying online. Moreover, increase in spending income, especially in the developing countries is driving the market. In addition to the above factors, other factors acting as drivers/constraints to the industry are available in the report along with a detailed description of their impact on the market. Industry Trends and Updates: - Product Innovations Companies are focusing on bringing in products specific to the consumer requirement. Gender specific products are also increasing at a rapid pace. - Organic products Growing concerns on the long term effects due to usage of cosmetics is forcing the companies to bring in organic products as well. This market is expected to increase during the forecasted period - Focus on Packaging Cosmetics Manufacturers profiling: The report also provides supplier intelligence which includes information such as top players in the industry (Procter and Gamble, Johnson and Johnson, L'Oreal, Avon, Henkel, Estee Lauder, etc among others). This also gives information on the supplier's market share, competitive landscape as well. Key Topics Covered: 1. Introduction - Research Methodology 2. Executive Summary 3. Market Overview 4. Market Dynamics 5. Cosmetics Market Segmentation, Forecasts and Trends - by Volume, by Revenue 6. Global Vendor Market Share Analysis 7. Competitive Intelligence - Company Profiles 8. Investment Analysis 9. Future of Cosmetics Market Companies Mentioned - Avon - Bayer - Clarins - Estee Lauder - Henkel - Hindistan Unilever - Johnson and Johnson - L'Oreal - Procter and Gamble For more information visit http://www.researchandmarkets.com/research/jg..._cosmetics
JNJ: 99.90 (+0.88), EL: 89.35 (+1.33)
4 Great Stocks For Beginners
Matthew Frankel, The Motley Fool - Motley Fool - Sun Jul 26, 7:09AM CDT
If you're new to the stock market, it may be tempting to pour your money into "it" stocks like Netflix , Tesla , and Amazon.com . However, that's the exact opposite of what you should be doing. Instead, the primary objective of a new investor...
JNJ: 99.90 (+0.88), XOM: 82.54 (+0.06), CL: 68.97 (+0.58)
Is Bristol-Myers Squibb Outpacing Johnson & Johnson?
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 25, 9:03AM CDT
Source: Flickr user Paul A race for dominance in the anticoagulant market is heating up between Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ) with the winner standing to reap billions of dollars in additional revenue...
JNJ: 99.90 (+0.88), BMY: 64.48 (-0.18)
A look at the largest companies in the S&P 500
By The Associated Press - AP - Fri Jul 24, 6:08PM CDT
Amazon surpassed the world's largest retailer, Wal-Mart Stores Inc., in market value Friday, on the back of a strong earnings report. Amazon shares closed up nearly 10 percent, giving the Seattle company a market value of $247.77 billion, versus $230.53 billion for Wal-Mart.
AMZN: 527.40 (+1.37), GE: 26.16 (+0.06), FB: 95.91 (+0.62), PFE: 35.68 (+0.33), DIS: 119.29 (+0.83), WMT: 72.38 (+0.28), XOM: 82.54 (+0.06), BAC: 18.10 (+0.22), WFC: 57.99 (+0.59), GOOG: 624.31 (-3.69), JNJ: 99.90 (+0.88), GOOGL: 654.81 (-4.85), PG: 80.85 (+0.62), MSFT: 46.50 (+1.16), AAPL: 122.51 (-0.87)
Bristol-Myers wins approval for 1st hepatitis C type 3 drug
By LINDA A. JOHNSON - AP - Fri Jul 24, 4:57PM CDT
TRENTON, N.J. (AP) — An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options — all much more effective but extremely costly — for patients with the liver-destroying virus.
JNJ: 99.90 (+0.88), GILD: 116.71 (+3.64), MRK: 58.72 (+1.20), BMY: 64.48 (-0.18)
After Yesterday's Decline of 1.04%, Johnson & Johnson Offers Investors Better Value
Comtex SmarTrend(R) - Fri Jul 24, 4:56PM CDT
Johnson & Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $99.05 to a high of $99.95. Yesterday, the shares fell 1.0%, which took the trading range below the 3-day low of $99.73 on volume of 5.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
JNJ: 99.90 (+0.88)
